Jalupro Young Eye is specifically formulated for the delicate skin around the eyes. This injectable treatment targets periorbital aging symptoms by restoring collagen production, skin thickness, density and resilience. Symptoms linked to collagen decrease and thinking of the skin such as dark circles, fine lines, and sagging will decrease for restored youthful appearance. Combining our signature amino acids, peptides, and bi-density hyaluronic acid, it stimulates collagen production, improves overall firmness, giving patients a refreshed and youthful appearance around the eyes.
Key Benefits:
Targeted Treatment: Jalupro Young Eye is uniquely designed for the sensitive periocular area, providing specific collagen support and hydration where it’s most needed.
Peptides and Amino Acids: This combination revitalizes the delicate eye area by promoting collagen synthesis and restoring skin strength
Reduction of symptoms: restoring skin quality and density will decrease symptoms like fine lines, sagging or dark circles
Why Jalupro Young Eye is Different:
Tailored for the Eye Area: Jalupro Young Eye is carefully formulated for the unique needs of the under-eye region, offering a more specialized treatment to aging problems of the area.
Holistic approach: Jalupro is not a symptomatic treatment. It goes beyond to tackle one of the root cause of skin aging. The same goes with our approach that is the treatment of the full periorbital area, not only the under-eye area, in order to give what you really deserve.
Why Jalupro Young Eye is Different:
Tailored for the Eye Area: Jalupro Young Eye is carefully formulated for the unique needs of the under-eye region, offering a more specialized treatment to aging problems of the area.
Holistic approach: Jalupro is not a symptomatic treatment. It goes beyond to tackle one of the root cause of skin aging. The same goes with our approach that is the treatment of the full periorbital area, not only the under-eye area, in order to give what you really deserve.






Reviews
There are no reviews yet.